BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6:637-56. [PMID: 23141799 DOI: 10.1016/j.molonc.2012.09.003] [Cited by in Crossref: 217] [Cited by in F6Publishing: 204] [Article Influence: 21.7] [Reference Citation Analysis]
Number Citing Articles
1 Winkler R, Mägdefrau AS, Piskor EM, Kleemann M, Beyer M, Linke K, Hansen L, Schaffer AM, Hoffmann ME, Poepsel S, Heyd F, Beli P, Möröy T, Mahboobi S, Krämer OH, Kosan C. Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. Oncogene 2022. [PMID: 36068335 DOI: 10.1038/s41388-022-02450-3] [Reference Citation Analysis]
2 Dewi C, Fristiohady A, Amalia R, Khairul Ikram NK, Ibrahim S, Muchtaridi M. Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line. Molecules 2022;27:3661. [PMID: 35744786 DOI: 10.3390/molecules27123661] [Reference Citation Analysis]
3 Kaya Çakir H, Eroglu O. In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting. Iran J Basic Med Sci 2021;24:1515-22. [PMID: 35317122 DOI: 10.22038/IJBMS.2021.58393.12971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Jiang BE, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang HK, Pang X, Yu LF. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Eur J Med Chem 2022;227:113893. [PMID: 34656899 DOI: 10.1016/j.ejmech.2021.113893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fernández-Serrano M, Winkler R, Santos JC, Le Pannérer MM, Buschbeck M, Roué G. Histone Modifications and Their Targeting in Lymphoid Malignancies. Int J Mol Sci 2021;23:253. [PMID: 35008680 DOI: 10.3390/ijms23010253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu Q, Zhang B, Wang Y, Wang X, Gou S. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. Eur J Med Chem 2021;229:114058. [PMID: 34954595 DOI: 10.1016/j.ejmech.2021.114058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mao P, He W, Mai X, Feng L, Li N, Liao Y, Zhu C, Li J, Chen T, Liu S, Zhang Q, He L. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 2021. [DOI: 10.1016/j.bmc.2021.116599] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang H, Shi L, Wang Z. A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. Front Oncol 2021;11:756817. [PMID: 34804949 DOI: 10.3389/fonc.2021.756817] [Reference Citation Analysis]
9 King J, Patel M, Chandrasekaran S. Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective. Metabolites 2021;11:792. [PMID: 34822450 DOI: 10.3390/metabo11110792] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
10 Selg C, Schöler A, Schliehe-Diecks J, Hanl M, Sinatra L, Borkhardt A, Sárosi MB, Bhatia S, Hey-Hawkins E, Hansen FK. Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile. Chem Sci 2021;12:11873-81. [PMID: 34659728 DOI: 10.1039/d1sc02268g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tandon S, Bartram J, Kyriakopoulou L, Kanwar N, Lo W, Davidson S, Punnett A, Shlien A, Hitzler J, Malkin D, Villani A, Abla O. Failure of Romidepsin to Treat Relapsed/Refractory Peripheral T-Cell Lymphoma in Children: A Single-center Experience. J Pediatr Hematol Oncol 2021;43:e745-8. [PMID: 32427705 DOI: 10.1097/MPH.0000000000001824] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Richardson P. Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opin Drug Discov 2021;:1-26. [PMID: 34074189 DOI: 10.1080/17460441.2021.1933427] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
13 An X, Wei Z, Ran B, Tian H, Gu H, Liu Y, Cui H, Zhu S. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells. Anticancer Agents Med Chem 2020;20:2114-24. [PMID: 32593284 DOI: 10.2174/1871520620666200627204857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Zhang Q, Wang Z, Chen X, Qiu H, Gu Y, Wang N, Wang T, Wang Z, Ma H, Zhao Y, Zhang B. 8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1. Int J Mol Sci 2021;22:5516. [PMID: 34073721 DOI: 10.3390/ijms22115516] [Reference Citation Analysis]
15 Feng C, Cai XW, Su YN, Li L, Chen S, He XJ. Arabidopsis RPD3-like histone deacetylases form multiple complexes involved in stress response. J Genet Genomics 2021;48:369-83. [PMID: 34144927 DOI: 10.1016/j.jgg.2021.04.004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Vaughan HJ, Zamboni CG, Radant NP, Bhardwaj P, Revai Lechtich E, Hassan LF, Shah K, Green JJ. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics 2021;21:377-88. [PMID: 34189258 DOI: 10.1016/j.omto.2021.04.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
17 Naz S, Banerjee T, Totsingan F, Woody K, Gross RA, Santra S. Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors. Nanotheranostics 2021;5:391-404. [PMID: 33912379 DOI: 10.7150/ntno.57675] [Reference Citation Analysis]
18 Mierziak J, Burgberger M, Wojtasik W. 3-Hydroxybutyrate as a Metabolite and a Signal Molecule Regulating Processes of Living Organisms. Biomolecules 2021;11:402. [PMID: 33803253 DOI: 10.3390/biom11030402] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
19 Tan JY, Wijesinghe IVS, Alfarizal Kamarudin MN, Parhar I. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies. Cancers (Basel) 2021;13:607. [PMID: 33557011 DOI: 10.3390/cancers13040607] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Chebly A, Chouery E, Ropio J, Kourie HR, Beylot-Barry M, Merlio JP, Tomb R, Chevret E. Diagnosis and treatment of lymphomas in the era of epigenetics. Blood Rev 2021;48:100782. [PMID: 33229141 DOI: 10.1016/j.blre.2020.100782] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Rodrigues Moita AJ, Bandolik JJ, Hansen FK, Kurz T, Hamacher A, Kassack MU. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors. Int J Mol Sci 2020;21:E8300. [PMID: 33167494 DOI: 10.3390/ijms21218300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Huang F, Sun J, Chen W, He X, Zhu Y, Dong H, Wang H, Li Z, Zhang L, Khaled S, Marcucci G, Huang J, Li L. HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML. Aging (Albany NY) 2020;12:16759-74. [PMID: 32726753 DOI: 10.18632/aging.103605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Huang G, Pan ST. ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer. Oxid Med Cell Longev 2020;2020:5047987. [PMID: 32774675 DOI: 10.1155/2020/5047987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
24 Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y, Wang Y. The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res 2020;39:138. [PMID: 32682428 DOI: 10.1186/s13046-020-01643-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
25 Dewaker V, Srivastava AK, Arora A, Prabhakar YS. Investigation of HDAC8-ligands’ intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents. Journal of Biomolecular Structure and Dynamics 2021;39:4726-51. [DOI: 10.1080/07391102.2020.1780940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Hanif M, Arshad J, Astin JW, Rana Z, Zafar A, Movassaghi S, Leung E, Patel K, Söhnel T, Reynisson J, Sarojini V, Rosengren RJ, Jamieson SMF, Hartinger CG. A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. Angew Chem Int Ed Engl 2020;59:14609-14. [PMID: 32431061 DOI: 10.1002/anie.202005758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kulka LAM, Fangmann PV, Panfilova D, Olzscha H. Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Front Cell Dev Biol 2020;8:425. [PMID: 32582706 DOI: 10.3389/fcell.2020.00425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
28 Trivedi R, Jurivich DA. A molecular perspective on age-dependent changes to the heat shock axis. Exp Gerontol 2020;137:110969. [PMID: 32407864 DOI: 10.1016/j.exger.2020.110969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 He J, Wang S, Liu X, Lin R, Deng F, Jia Z, Zhang C, Li Z, Zhu H, Tang L, Yang P, He D, Jia Q, Zhang Y. Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group. Front Chem 2020;8:256. [PMID: 32351936 DOI: 10.3389/fchem.2020.00256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Liu J, Zhou J, He F, Gao L, Wen Y, Gao L, Wang P, Kang D, Hu L. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening. European Journal of Medicinal Chemistry 2020;192:112189. [DOI: 10.1016/j.ejmech.2020.112189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
31 Hanz SZ, Adeuyan O, Lieberman G, Hennika T. Clinical trials using molecular stratification of pediatric brain tumors. Transl Pediatr 2020;9:144-56. [PMID: 32477915 DOI: 10.21037/tp.2020.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yang F, Han L, Zhao N, Yang Y, Ge D, Zhang H, Chen Y. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities. Future Med Chem 2020;12:655-72. [PMID: 32202140 DOI: 10.4155/fmc-2019-0343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study. Future Oncol 2020;16:619-29. [PMID: 32125175 DOI: 10.2217/fon-2020-0023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
34 Chen J, Li N, Liu B, Ling J, Yang W, Pang X, Li T. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways. Life Sci 2020;248:117469. [PMID: 32109485 DOI: 10.1016/j.lfs.2020.117469] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
35 Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer 2020;19:5. [PMID: 31910827 DOI: 10.1186/s12943-019-1127-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 59] [Article Influence: 18.0] [Reference Citation Analysis]
36 Su L, Wang S, Yuan T, Xie X, Fu X, Ji P, Zhong L, Liu W. Anti-oral Squamous Cell Carcinoma Effects of a Potent TAZ Inhibitor AR-42. J Cancer 2020;11:364-73. [PMID: 31897232 DOI: 10.7150/jca.32436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
37 Banerjee S, Amin SA, Adhikari N, Jha T. Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors. Journal of Biomolecular Structure and Dynamics 2020;38:5513-25. [DOI: 10.1080/07391102.2019.1704881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Zhu Y, Yuan T, Zhang Y, Shi J, Bai L, Duan X, Tong R, Zhong L. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma. Drug Des Devel Ther 2019;13:4321-30. [PMID: 31908417 DOI: 10.2147/DDDT.S211665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
39 Ghasemi S. Cancer's epigenetic drugs: where are they in the cancer medicines? Pharmacogenomics J. 2020;20:367-379. [PMID: 31819161 DOI: 10.1038/s41397-019-0138-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
40 Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery 2020;15:243-58. [DOI: 10.1080/17460441.2020.1696769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Palomo M, Vera M, Martin S, Torramadé-Moix S, Martinez-Sanchez J, Belen Moreno A, Carreras E, Escolar G, Cases A, Díaz-Ricart M. Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. J Cell Mol Med 2020;24:1713-23. [PMID: 31782253 DOI: 10.1111/jcmm.14865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
42 Krieger V, Hamacher A, Cao F, Stenzel K, Gertzen CGW, Schäker-hübner L, Kurz T, Gohlke H, Dekker FJ, Kassack MU, Hansen FK. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties. J Med Chem 2019;62:11260-79. [DOI: 10.1021/acs.jmedchem.9b01489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
43 Kahanovitch U, Olsen ML. Glial SIK3: A central player in ion and volume homeostasis in Drosophila peripheral nerves. J Cell Biol 2019;218:3888-9. [PMID: 31723008 DOI: 10.1083/jcb.201910017] [Reference Citation Analysis]
44 Cortiguera MG, García-Gaipo L, Wagner SD, León J, Batlle-López A, Delgado MD. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Sci Rep 2019;9:16495. [PMID: 31712669 DOI: 10.1038/s41598-019-52714-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
45 Yang L, Liu Y, Fan M, Zhu G, Jin H, Liang J, Liu Z, Huang Z, Zhang L. Identification and characterization of benzo[d]oxazol-2(3H)-one derivatives as the first potent and selective small-molecule inhibitors of chromodomain protein CDYL. European Journal of Medicinal Chemistry 2019;182:111656. [DOI: 10.1016/j.ejmech.2019.111656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Luque-Martin R, Van den Bossche J, Furze RC, Neele AE, van der Velden S, Gijbels MJJ, van Roomen CPPA, Bernard SG, de Jonge WJ, Rioja I, Prinjha RK, Lewis HD, Mander PK, de Winther MPJ. Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis. Front Pharmacol. 2019;10:1242. [PMID: 31736752 DOI: 10.3389/fphar.2019.01242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
47 Tsai CH, Li CH, Liao PL, Chang YW, Cheng YW, Kang JJ. Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKCα-mediated AHR-HDAC interactions. Biochim Biophys Acta Mol Cell Res 2020;1867:118564. [PMID: 31672612 DOI: 10.1016/j.bbamcr.2019.118564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Latusz J, Maćkowiak M. Early-life blockade of NMDA receptors induces epigenetic abnormalities in the adult medial prefrontal cortex: possible involvement in memory impairment in trace fear conditioning. Psychopharmacology (Berl) 2020;237:231-48. [PMID: 31654083 DOI: 10.1007/s00213-019-05362-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Erdeljac N, Bussmann K, Schöler A, Hansen FK, Gilmour R. Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE. ACS Med Chem Lett 2019;10:1336-40. [PMID: 31531206 DOI: 10.1021/acsmedchemlett.9b00287] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
50 Tsai DY, Hung KH, Chang CW, Lin KI. Regulatory mechanisms of B cell responses and the implication in B cell-related diseases. J Biomed Sci 2019;26:64. [PMID: 31472685 DOI: 10.1186/s12929-019-0558-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
51 Baek MH, Park JY, Park Y, Kim KR, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma. Jpn J Clin Oncol 2019;49:719-26. [PMID: 31329907 DOI: 10.1093/jjco/hyz059] [Reference Citation Analysis]
52 Yang Z, Shen M, Tang M, Zhang W, Cui X, Zhang Z, Pei H, Li Y, Hu M, Bai P, Chen L. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy. Eur J Med Chem 2019;178:116-30. [PMID: 31177073 DOI: 10.1016/j.ejmech.2019.05.089] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
53 Ng SY, Jacobsen ED. Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies. Hematol Oncol Clin North Am 2019;33:657-68. [PMID: 31229161 DOI: 10.1016/j.hoc.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Olzscha H. Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated. Biological Chemistry 2019;400:895-915. [DOI: 10.1515/hsz-2018-0458] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
55 Maiti A, Qi Q, Peng X, Yan L, Takabe K, Hait NC. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells. Int J Oncol 2019;55:116-30. [PMID: 31059004 DOI: 10.3892/ijo.2019.4796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
56 Mahindra A, Millard CJ, Black I, Archibald LJ, Schwabe JWR, Jamieson AG. Synthesis of HDAC Substrate Peptidomimetic Inhibitors Using Fmoc Amino Acids Incorporating Zinc-Binding Groups. Org Lett 2019;21:3178-82. [PMID: 30998366 DOI: 10.1021/acs.orglett.9b00885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
57 Dimopoulos K, Grønbæk K. Epigenetic therapy in hematological cancers. APMIS 2019;127:316-28. [DOI: 10.1111/apm.12906] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
58 Song Q, Li M, Fan C, Liu Y, Zheng L, Bao Y, Sun L, Yu C, Song Z, Sun Y, Wang G, Huang Y, Li Y. A novel benzamine lead compound of histone deacetylase inhibitor ZINC24469384 can suppresses HepG2 cells proliferation by upregulating NR1H4. Sci Rep 2019;9:2350. [PMID: 30787420 DOI: 10.1038/s41598-019-39487-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Nakamura S, Haga S, Kimura K, Matsuyama S. Propionate and butyrate induce gene expression of monocarboxylate transporter 4 and cluster of differentiation 147 in cultured rumen epithelial cells derived from preweaning dairy calves. J Anim Sci 2018;96:4902-11. [PMID: 30215729 DOI: 10.1093/jas/sky334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Mackwitz MKW, Hesping E, Antonova-Koch Y, Diedrich D, Woldearegai TG, Skinner-Adams T, Clarke M, Schöler A, Limbach L, Kurz T, Winzeler EA, Held J, Andrews KT, Hansen FK. Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity. ChemMedChem 2019;14:912-26. [PMID: 30664827 DOI: 10.1002/cmdc.201800808] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
61 Mitsiogianni M, Mantso T, Trafalis DT, Vasantha Rupasinghe HP, Zoumpourlis V, Franco R, Botaitis S, Pappa A, Panayiotidis MI. Allyl isothiocyanate regulates lysine acetylation and methylation marks in an experimental model of malignant melanoma. Eur J Nutr 2020;59:557-69. [PMID: 30762097 DOI: 10.1007/s00394-019-01925-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
62 Tian S, Lei I, Gao W, Liu L, Guo Y, Creech J, Herron TJ, Xian S, Ma PX, Eugene Chen Y, Li Y, Alam HB, Wang Z. HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction. EBioMedicine 2019;39:83-94. [PMID: 30552062 DOI: 10.1016/j.ebiom.2018.12.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
63 Amin SA, Adhikari N, Jha T, Ghosh B. Designing potential HDAC3 inhibitors to improve memory and learning. Journal of Biomolecular Structure and Dynamics 2019;37:2133-42. [DOI: 10.1080/07391102.2018.1477625] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
64 Reßing N, Marquardt V, Gertzen CGW, Schöler A, Schramm A, Kurz T, Gohlke H, Aigner A, Remke M, Hansen FK. Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. Medchemcomm 2019;10:1109-15. [PMID: 31391882 DOI: 10.1039/c8md00454d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lin WC, Hsu FS, Kuo KL, Liu SH, Shun CT, Shi CS, Chang HC, Tsai YC, Lin MC, Wu JT, Kuo Y, Chow PM, Liao SM, Yang SP, Hong JY, Huang KH. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma. J Mol Med (Berl) 2018;96:1307-18. [PMID: 30288546 DOI: 10.1007/s00109-018-1697-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
66 Sangwan R, Rajan R, Mandal PK. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European Journal of Medicinal Chemistry 2018;158:620-706. [DOI: 10.1016/j.ejmech.2018.08.073] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
67 Gupta N, Shyamasundar S, Patnala R, Karthikeyan A, Arumugam TV, Ling E, Dheen ST. Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies. Expert Opinion on Therapeutic Targets 2018;22:765-81. [DOI: 10.1080/14728222.2018.1515917] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
68 Diedrich D, Stenzel K, Hesping E, Antonova-Koch Y, Gebru T, Duffy S, Fisher G, Schöler A, Meister S, Kurz T, Avery VM, Winzeler EA, Held J, Andrews KT, Hansen FK. One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. Eur J Med Chem 2018;158:801-13. [PMID: 30245402 DOI: 10.1016/j.ejmech.2018.09.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
69 Zhong L, Zhou S, Tong R, Shi J, Bai L, Zhu Y, Duan X, Liu W, Bao J, Su L, Peng Q. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Invest New Drugs 2019;37:616-24. [DOI: 10.1007/s10637-018-0651-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
70 Wu JC, Jiang HM, Yang XH, Zheng HC. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid. Cancer Med 2018;7:4554-69. [PMID: 30091530 DOI: 10.1002/cam4.1634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
71 Chen X, Li W, Xu C, Wang J, Zhu B, Huang Q, Chen D, Sheng J, Zou Y, Lee YM, Tan R, Shen P, Wong YK, Lin Q, Wang J, Hua Z. Comparative profiling of analog targets: a case study on resveratrol for mouse melanoma metastasis suppression. Theranostics 2018;8:3504-16. [PMID: 30026862 DOI: 10.7150/thno.24336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
72 Mikesch J, Schwammbach D, Hartmann W, Schmidt L, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-tidow C, Berdel WE, Arteaga M. Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. Eur Respir J 2018;52:1701637. [DOI: 10.1183/13993003.01637-2017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
73 Mervis JS, McGee JS. Epigenetic therapy and dermatologic disease: moving beyond CTCL. J Dermatolog Treat 2019;30:68-73. [PMID: 29726727 DOI: 10.1080/09546634.2018.1473550] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
74 Garmpis N, Damaskos C, Garmpi A, Kalampokas E, Kalampokas T, Spartalis E, Daskalopoulou A, Valsami S, Kontos M, Nonni A, Kontzoglou K, Perrea D, Nikiteas N, Dimitroulis D. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. Cancer Genomics Proteomics 2017;14:299-313. [PMID: 28870998 DOI: 10.21873/cgp.20041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
75 Lin H, Li Q, Li Q, Zhu J, Gu K, Jiang X, Hu Q, Feng F, Qu W, Chen Y, Sun H. Small molecule KDM4s inhibitors as anti-cancer agents. J Enzyme Inhib Med Chem. 2018;33:777-793. [PMID: 29651880 DOI: 10.1080/14756366.2018.1455676] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
76 Manea SA, Antonescu ML, Fenyo IM, Raicu M, Simionescu M, Manea A. Epigenetic regulation of vascular NADPH oxidase expression and reactive oxygen species production by histone deacetylase-dependent mechanisms in experimental diabetes. Redox Biol 2018;16:332-43. [PMID: 29587244 DOI: 10.1016/j.redox.2018.03.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
77 Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors. Oncotarget 2016;7:79064-75. [PMID: 27738323 DOI: 10.18632/oncotarget.12594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
78 Chidambaram A, Sundararaju K, Chidambaram RK, Subbiah R, Jayaraj JM, Muthusamy K, Vilwanathan R. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line. J Cell Physiol 2018;233:5293-309. [PMID: 29215703 DOI: 10.1002/jcp.26333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
79 Tang S, Ma D, Cheng B, Fang Q, Kuang X, Yu K, Wang W, Hu B, Wang J. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp Cell Res 2018;363:196-207. [PMID: 29317217 DOI: 10.1016/j.yexcr.2018.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
80 Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM, Stiborová M. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells. Int J Mol Sci 2018;19:E164. [PMID: 29304031 DOI: 10.3390/ijms19010164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
81 Mcleod AB, Stice JP, Wardell SE, Alley HM, Chang C, Mcdonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer. Prostate 2018;78:266-77. [DOI: 10.1002/pros.23467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
82 Shi M, Lu XJ, Zhang J, Diao H, Li G, Xu L, Wang T, Wei J, Meng W, Ma JL, Yu H, Wang YG. Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. Oncotarget 2016;7:22623-31. [PMID: 26980707 DOI: 10.18632/oncotarget.8033] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
83 Tang Z, Ding S, Huang H, Luo P, Qing B, Zhang S, Tang R. HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8. Biological Chemistry 2017;398:1347-56. [DOI: 10.1515/hsz-2017-0155] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
84 Uba AI, Yelekçi K. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. J Biomol Struct Dyn 2018;36:3231-45. [PMID: 28938863 DOI: 10.1080/07391102.2017.1384402] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
85 Newman JC, Verdin E. β-Hydroxybutyrate: A Signaling Metabolite. Annu Rev Nutr 2017;37:51-76. [PMID: 28826372 DOI: 10.1146/annurev-nutr-071816-064916] [Cited by in Crossref: 190] [Cited by in F6Publishing: 240] [Article Influence: 38.0] [Reference Citation Analysis]
86 Alzrigat M, Párraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: From mechanisms to therapy. Semin Cancer Biol 2018;51:101-15. [PMID: 28962927 DOI: 10.1016/j.semcancer.2017.09.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
87 Groselj B, Ruan JL, Scott H, Gorrill J, Nicholson J, Kelly J, Anbalagan S, Thompson J, Stratford MRL, Jevons SJ, Hammond EM, Scudamore CL, Kerr M, Kiltie AE. Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. Mol Cancer Ther 2018;17:381-92. [PMID: 28839000 DOI: 10.1158/1535-7163.MCT-17-0011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
88 Chen YJ, Wang WH, Wu WY, Hsu CC, Wei LR, Wang SF, Hsu YW, Liaw CC, Tsai WC. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways. PLoS One 2017;12:e0183368. [PMID: 28829799 DOI: 10.1371/journal.pone.0183368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
89 Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev 2018;32:8-28. [PMID: 28802908 DOI: 10.1016/j.blre.2017.08.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
90 Li J, Qian C, Zhou Q, Li J, Li K, Yi P. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma. Biochem Biophys Res Commun 2017;491:939-45. [PMID: 28756223 DOI: 10.1016/j.bbrc.2017.07.139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
91 Oh BR, Suh DH, Bae D, Ha N, Choi YI, Yoo HJ, Park JK, Lee EY, Lee EB, Song YW. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro. Arthritis Res Ther 2017;19:154. [PMID: 28673326 DOI: 10.1186/s13075-017-1357-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
92 Krieger V, Hamacher A, Gertzen CGW, Senger J, Zwinderman MRH, Marek M, Romier C, Dekker FJ, Kurz T, Jung M, Gohlke H, Kassack MU, Hansen FK. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups. J Med Chem 2017;60:5493-506. [PMID: 28574690 DOI: 10.1021/acs.jmedchem.7b00197] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
93 Qu K, Zaba LC, Satpathy AT, Giresi PG, Li R, Jin Y, Armstrong R, Jin C, Schmitt N, Rahbar Z, Ueno H, Greenleaf WJ, Kim YH, Chang HY. Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell 2017;32:27-41.e4. [PMID: 28625481 DOI: 10.1016/j.ccell.2017.05.008] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 15.6] [Reference Citation Analysis]
94 Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, Li J, Zhang B, Hou Y, Laudato S, Lipka DB, Schott J, Bierhoff H, Assenov Y, Helf M, Ressnerova A, Islam MS, Lindroth AM, Haas S, Essers M, Imbusch CD, Brors B, Oehme I, Witt O, Lübbert M, Mallm JP, Rippe K, Will R, Weichenhan D, Stoecklin G, Gerhäuser C, Oakes CC, Wang T, Plass C. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet 2017;49:1052-60. [PMID: 28604729 DOI: 10.1038/ng.3889] [Cited by in Crossref: 134] [Cited by in F6Publishing: 132] [Article Influence: 26.8] [Reference Citation Analysis]
95 Halaburková A, Jendželovský R, Kovaľ J, Herceg Z, Fedoročko P, Ghantous A. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A. Clin Epigenetics 2017;9:62. [PMID: 28603560 DOI: 10.1186/s13148-017-0359-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
96 Cheng-Sánchez I, García-Ruiz C, Guerrero-Vásquez GA, Sarabia F. An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues. J Org Chem 2017;82:4744-57. [PMID: 28397496 DOI: 10.1021/acs.joc.7b00424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
97 Ratajczak MZ, Ratajczak J, Suszynska M, Miller DM, Kucia M, Shin DM. A Novel View of the Adult Stem Cell Compartment From the Perspective of a Quiescent Population of Very Small Embryonic-Like Stem Cells. Circ Res 2017;120:166-78. [PMID: 28057792 DOI: 10.1161/CIRCRESAHA.116.309362] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
98 Chen D, Xu M, Wu B, Chen L. Histone deacetylases in hearing loss: Current perspectives for therapy. J Otol 2017;12:47-54. [PMID: 29937837 DOI: 10.1016/j.joto.2017.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
99 Tarasenko N, Nudelman A, Rozic G, Cutts SM, Rephaeli A. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Invest New Drugs 2017;35:412-26. [DOI: 10.1007/s10637-017-0448-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
100 Ahn MY, Yoon JH. Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med. 2017;46:276-283. [PMID: 28178760 DOI: 10.1111/jop.12560] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
101 Tan X, Feng L, Huang X, Yang Y, Yang C, Gao Y. Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth. J Cell Mol Med 2017;21:2022-35. [PMID: 28266122 DOI: 10.1111/jcmm.13122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
102 Sun W, Huang H, He B, Hu D, Li P, Yu Y, Zhou X, Lv Z, Zhou L, Hu T, Yao Z, Lu M, Shen X, Zheng Z. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochemical Pharmacology 2017;127:90-100. [DOI: 10.1016/j.bcp.2016.12.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
103 Pouliquen DL, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P, Grégoire M. Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. Oncotarget 2017;8:57552-73. [PMID: 28915695 DOI: 10.18632/oncotarget.15744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
104 Alfurhood JA, Sun H, Kabb CP, Tucker BS, Matthews JH, Luesch H, Sumerlin BS. Poly(N-(2-Hydroxypropyl) Methacrylamide)-Valproic Acid Conjugates as Block Copolymer Nanocarriers. Polym Chem 2017;8:4983-7. [PMID: 28959359 DOI: 10.1039/C7PY00196G] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
105 Podobinska M, Szablowska-Gadomska I, Augustyniak J, Sandvig I, Sandvig A, Buzanska L. Epigenetic Modulation of Stem Cells in Neurodevelopment: The Role of Methylation and Acetylation. Front Cell Neurosci 2017;11:23. [PMID: 28223921 DOI: 10.3389/fncel.2017.00023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
106 Hrgovic I, Doll M, Pinter A, Kaufmann R, Kippenberger S, Meissner M. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism. Exp Dermatol 2017;26:194-201. [DOI: 10.1111/exd.13159] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
107 Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q. Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. Trends Microbiol 2017;25:573-84. [PMID: 28139375 DOI: 10.1016/j.tim.2017.01.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
108 Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, Chang C, Gifford AJ, Tsoli M, Ziegler DS, Carcaboso AM, Becher OJ. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models. PLoS One 2017;12:e0169485. [PMID: 28052119 DOI: 10.1371/journal.pone.0169485] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
109 Qi Y, Wang D, Wang D, Jin T, Yang L, Wu H, Li Y, Zhao J, Du F, Song M, Wang R. HEDD: the human epigenetic drug database. Database (Oxford) 2016;2016:baw159. [PMID: 28025347 DOI: 10.1093/database/baw159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
110 Olzscha H, Fedorov O, Kessler BM, Knapp S, La Thangue NB. CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation. Cell Chem Biol 2017;24:9-23. [PMID: 27989401 DOI: 10.1016/j.chembiol.2016.11.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
111 Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk Lymphoma 2017;58:1880-6. [PMID: 27911138 DOI: 10.1080/10428194.2016.1263843] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
112 Porter NJ, Christianson NH, Decroos C, Christianson DW. Structural and Functional Influence of the Glycine-Rich Loop G302GGGY on the Catalytic Tyrosine of Histone Deacetylase 8. Biochemistry 2016;55:6718-29. [PMID: 27933794 DOI: 10.1021/acs.biochem.6b01014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
113 Brevini TA, Pennarossa G, Manzoni EF, Gandolfi CE, Zenobi A, Gandolfi F. The quest for an effective and safe personalized cell therapy using epigenetic tools. Clin Epigenetics 2016;8:119. [PMID: 27891192 DOI: 10.1186/s13148-016-0283-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
114 Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma 2017;58:1306-19. [PMID: 27813438 DOI: 10.1080/10428194.2016.1247956] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
115 Patnala R, Arumugam TV, Gupta N, Dheen ST. HDAC Inhibitor Sodium Butyrate-Mediated Epigenetic Regulation Enhances Neuroprotective Function of Microglia During Ischemic Stroke. Mol Neurobiol 2017;54:6391-411. [PMID: 27722928 DOI: 10.1007/s12035-016-0149-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 97] [Article Influence: 11.7] [Reference Citation Analysis]
116 Hrgovic I, Doll M, Kleemann J, Wang XF, Zoeller N, Pinter A, Kippenberger S, Kaufmann R, Meissner M. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer 2016;16:763. [PMID: 27716272 DOI: 10.1186/s12885-016-2807-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
117 Pidugu VR, Yarla NS, Pedada SR, Kalle AM, Satya AK. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity. Bioorg Med Chem 2016;24:5611-7. [PMID: 27665180 DOI: 10.1016/j.bmc.2016.09.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
118 Runcie AC, Chan KH, Zengerle M, Ciulli A. Chemical genetics approaches for selective intervention in epigenetics. Curr Opin Chem Biol 2016;33:186-94. [PMID: 27423045 DOI: 10.1016/j.cbpa.2016.06.031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
119 Reddy SA. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Crit Rev Oncol Hematol 2016;106:99-107. [PMID: 27637355 DOI: 10.1016/j.critrevonc.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
120 Serebryannyy LA, Cruz CM, de Lanerolle P. A Role for Nuclear Actin in HDAC 1 and 2 Regulation. Sci Rep 2016;6:28460. [PMID: 27345839 DOI: 10.1038/srep28460] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
121 Petrich A, Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma 2016;57:1755-65. [PMID: 27118119 DOI: 10.3109/10428194.2016.1160082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
122 Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, Wang YH, Deguchi A, Tanaka J, Maru Y, Motoji T. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight 2016;1:e85061. [PMID: 27699258 DOI: 10.1172/jci.insight.85061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
123 Bhaskara S. Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers. Cell Cycle 2015;14:1779-85. [PMID: 25942572 DOI: 10.1080/15384101.2015.1042634] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
124 Liu R, Wang J, Tang W, Fang H. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry 2016;24:1446-54. [DOI: 10.1016/j.bmc.2016.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
125 Gertz M, Steegborn C. Using mitochondrial sirtuins as drug targets: disease implications and available compounds. Cell Mol Life Sci 2016;73:2871-96. [PMID: 27007507 DOI: 10.1007/s00018-016-2180-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
126 Zinzani PL, Pellegrini C, Cerciello G, Monaco F, Volpetti S, Peli A, Angelucci E, Corradini P, Cox MC, Guarini A, Musso M, Bresciani P, Amato G, Billio A, Caparrotti G, Figuera A, Nassi L, Gaudio F, Grossi A, Onida F, Merli M, Rigacci L, Argnani L. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia & Lymphoma 2016;57:2370-4. [DOI: 10.3109/10428194.2015.1137292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
127 Asaba Y, Asayama S, Kawakami H. Design of epigenetics control carrier for simultaneous transfection of histone acetyltransferase with histone deacetylase inhibitor to continuous histone acetylation. Polym J 2016;48:561-4. [DOI: 10.1038/pj.2015.129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Mol Cancer Ther 2016;15:830-41. [PMID: 26809490 DOI: 10.1158/1535-7163.MCT-15-0240-T] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
129 Gantt SM, Decroos C, Lee MS, Gullett LE, Bowman CM, Christianson DW, Fierke CA. General Base-General Acid Catalysis in Human Histone Deacetylase 8. Biochemistry 2016;55:820-32. [PMID: 26806311 DOI: 10.1021/acs.biochem.5b01327] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
130 Wang L, Li H, Ren Y, Zou S, Fang W, Jiang X, Jia L, Li M, Liu X, Yuan X, Chen G, Yang J, Wu C. Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms. Cell Death Dis 2016;7:e2063. [PMID: 26794658 DOI: 10.1038/cddis.2015.328] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
131 Ligon CO, Moloney RD, Greenwood-van Meerveld B. Targeting Epigenetic Mechanisms for Chronic Pain: A Valid Approach for the Development of Novel Therapeutics. Journal of Pharmacology and Experimental Therapeutics 2016;357:84-93. [DOI: 10.1124/jpet.115.231670] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
132 Wen J, Bao Y, Niu Q, Yang J, Fan Y, Li J, Jing Y, Zhao L, Liu D. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy. Eur J Med Chem 2016;109:350-9. [PMID: 26814680 DOI: 10.1016/j.ejmech.2016.01.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
133 Wen J, Niu Q, Liu J, Bao Y, Yang J, Luan S, Fan Y, Liu D, Zhao L. Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1 H -pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study. Bioorganic & Medicinal Chemistry Letters 2016;26:375-9. [DOI: 10.1016/j.bmcl.2015.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
134 Kim SM, Park KC, Jeon JY, Kim BW, Kim HK, Chang HJ, Choi SH, Park CS, Chang HS. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer. BMC Cancer 2015;15:1003. [PMID: 26698299 DOI: 10.1186/s12885-015-1982-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
135 Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, Chen J. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia 2015;17:239-55. [PMID: 25810009 DOI: 10.1016/j.neo.2015.02.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 12.1] [Reference Citation Analysis]
136 Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, Zhao LY, Li JL, Wang Y, Wang Y, Ma H, Hodder P, Roush WR, Liao D. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem Biol 2015;22:273-84. [PMID: 25699604 DOI: 10.1016/j.chembiol.2014.12.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
137 Hagelkruys A, Mattes K, Moos V, Rennmayr M, Ringbauer M, Sawicka A, Seiser C. Essential Nonredundant Function of the Catalytic Activity of Histone Deacetylase 2 in Mouse Development. Mol Cell Biol 2016;36:462-74. [PMID: 26598605 DOI: 10.1128/MCB.00639-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
138 Kratsman N, Getselter D, Elliott E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology. 2016;102:136-145. [PMID: 26577018 DOI: 10.1016/j.neuropharm.2015.11.003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 87] [Article Influence: 13.7] [Reference Citation Analysis]
139 García-Ruiz C, Cheng-Sánchez I, Sarabia F. Stereoselective Total Synthesis of (-)-Depudecin. Org Lett 2015;17:5558-61. [PMID: 26517569 DOI: 10.1021/acs.orglett.5b02697] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
140 Bhadra U, Mondal T, Bag I, Mukhopadhyay D, Das P, Parida BB, Mainkar PS, Reddy CR, Bhadra MP. HDAC inhibitor misprocesses bantam oncomiRNA, but stimulates hid induced apoptotic pathway. Sci Rep 2015;5:14747. [PMID: 26442596 DOI: 10.1038/srep14747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
141 Markozashvili D, Ribrag V, Vassetzky YS. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Invest New Drugs 2015;33:1280-91. [PMID: 26423245 DOI: 10.1007/s10637-015-0290-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Geeleher P, Loboda A, Lenkala D, Wang F, LaCroix B, Karovic S, Wang J, Nebozhyn M, Chisamore M, Hardwick J, Maitland ML, Huang RS. Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst 2015;107:djv247. [PMID: 26296641 DOI: 10.1093/jnci/djv247] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
143 Wang L, Hou X, Fu H, Pan X, Xu W, Tang W, Fang H. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry 2015;23:4364-74. [DOI: 10.1016/j.bmc.2015.06.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
144 Mahal K, Kahlen P, Biersack B, Schobert R. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide – A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Experimental Cell Research 2015;336:263-75. [DOI: 10.1016/j.yexcr.2015.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
145 Marlow LA, Bok I, Smallridge RC, Copland JA. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection. Endocr Relat Cancer 2015;22:777-92. [PMID: 26206775 DOI: 10.1530/ERC-14-0302] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
146 Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL. Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol 2015;90:624-8. [PMID: 25808664 DOI: 10.1002/ajh.24019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
147 Schmitz ML, de la Vega L. New Insights into the Role of Histone Deacetylases as Coactivators of Inflammatory Gene Expression. Antioxidants & Redox Signaling 2015;23:85-98. [DOI: 10.1089/ars.2013.5750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
148 Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist 2015;20:1084-91. [PMID: 26099743 DOI: 10.1634/theoncologist.2015-0043] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
149 Zwergel C, Valente S, Jacob C, Mai A. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opinion on Drug Discovery 2015;10:599-613. [DOI: 10.1517/17460441.2015.1038236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
150 Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. Biochem J 2015;465:1-26. [PMID: 25631680 DOI: 10.1042/BJ20140496] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
151 Yang JS, Lee C, Cho M, Kim H, Kim JH, Choi S, Oh SJ, Kang JS, Jeong JH, Kim HJ, Han G. Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization. J Med Chem 2015;58:3512-21. [PMID: 25811792 DOI: 10.1021/acs.jmedchem.5b00062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
152 Karsli-ceppioglu S, Ngollo M, Adjakly M, Dagdemir A, Judes G, Lebert A, Boiteux J, Penault-llorca F, Bignon Y, Guy L, Bernard-gallon D. Genome-Wide DNA Methylation Modified by Soy Phytoestrogens: Role for Epigenetic Therapeutics in Prostate Cancer? OMICS: A Journal of Integrative Biology 2015;19:209-19. [DOI: 10.1089/omi.2014.0142] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
153 Samarakkody A, Abbas A, Scheidegger A, Warns J, Nnoli O, Jokinen B, Zarns K, Kubat B, Dhasarathy A, Nechaev S. RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition. Nucleic Acids Res 2015;43:3938-49. [PMID: 25820424 DOI: 10.1093/nar/gkv263] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
154 Decroos C, Clausen DJ, Haines BE, Wiest O, Williams RM, Christianson DW. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. Biochemistry 2015;54:2126-35. [PMID: 25793284 DOI: 10.1021/acs.biochem.5b00010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
155 Swierczynski S, Klieser E, Illig R, Alinger-Scharinger B, Kiesslich T, Neureiter D. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther. 2015;15:651-664. [PMID: 25766312 DOI: 10.1517/14712598.2015.1025047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
156 Nagai K. Phytanic acid induces Neuro2a cell death via histone deacetylase activation and mitochondrial dysfunction. Neurotoxicology and Teratology 2015;48:33-9. [DOI: 10.1016/j.ntt.2015.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
157 Picascia A, Grimaldi V, Pignalosa O, De Pascale MR, Schiano C, Napoli C. Epigenetic control of autoimmune diseases: From bench to bedside. Clinical Immunology 2015;157:1-15. [DOI: 10.1016/j.clim.2014.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
158 Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015;20:718-35. [PMID: 25687212 DOI: 10.1016/j.drudis.2015.01.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 15.6] [Reference Citation Analysis]
159 Mahal K, Schruefer S, Steinemann G, Rausch F, Schobert R, Biersack B, Höpfner M. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. Cancer Chemother Pharmacol 2015;75:691-700. [PMID: 25618416 DOI: 10.1007/s00280-015-2685-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
160 Deschamps N, Simões-Pires CA, Carrupt PA, Nurisso A. How the flexibility of human histone deacetylases influences ligand binding: an overview. Drug Discov Today 2015;20:736-42. [PMID: 25597521 DOI: 10.1016/j.drudis.2015.01.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
161 Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 2015;17:862-7. [PMID: 25572329 DOI: 10.1093/neuonc/nou350] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
162 Zhu L, Wu K, Ma S, Zhang S. HDAC Inhibitors: A New Radiosensitizer for Non-small-cell Lung Cancer. Tumori 2015;101:257-62. [DOI: 10.5301/tj.5000347] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
163 Liu Y, Lee H, Chen C, Lee C, Wang L, Pan S, Lai M, Yeh T, Liou J. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells. European Journal of Medicinal Chemistry 2015;89:320-30. [DOI: 10.1016/j.ejmech.2014.10.052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
164 Campbell GR, Bruckman RS, Chu YL, Spector SA. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem 2015;290:5028-40. [PMID: 25540204 DOI: 10.1074/jbc.M114.605428] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
165 Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis 2015;36:192-201. [PMID: 25477340 DOI: 10.1093/carcin/bgu238] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
166 Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol 2014;5:197-210. [PMID: 25469210 DOI: 10.1177/2040620714552614] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
167 Tran TA, Wichterman-Kouznetsova J, Varghese D, Huang R, Huang W, Becker M, Austin CP, Inglese J, Johnson RL, Martinez ED. Identification of small molecule modulators of gene transcription with anticancer activity. ACS Chem Biol 2014;9:2603-11. [PMID: 25188650 DOI: 10.1021/cb500532x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
168 Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L, Bensinger WI. Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Rev Hematol 2015;8:9-18. [PMID: 25410127 DOI: 10.1586/17474086.2015.983065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
169 Lu C, Zhang K, Zhang Y, Tan M, Li Y, He X, Zhang Y. Preparation and characterization of vorinostat-coated beads for profiling of novel target proteins. J Chromatogr A 2014;1372C:34-41. [PMID: 25465005 DOI: 10.1016/j.chroma.2014.10.098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
170 Alsarraf O, Fan J, Dahrouj M, Chou CJ, Yates PW, Crosson CE. Acetylation preserves retinal ganglion cell structure and function in a chronic model of ocular hypertension. Invest Ophthalmol Vis Sci 2014;55:7486-93. [PMID: 25358731 DOI: 10.1167/iovs.14-14792] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
171 Bodiford A, Bodge M, Talbott MS, Reddy NM. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets Ther 2014;7:1971-7. [PMID: 25368524 DOI: 10.2147/OTT.S59269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
172 Qi YF, Huang YX, Dong Y, Zheng LH, Bao YL, Sun LG, Wu Y, Yu CL, Jiang HY, Li YX. Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors. Comput Math Methods Med 2014;2014:867289. [PMID: 25371703 DOI: 10.1155/2014/867289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
173 Tasoulas J, Giaginis C, Patsouris E, Manolis E, Theocharis S. Histone deacetylase inhibitors in oral squamous cell carcinoma treatment. Expert Opin Investig Drugs 2015;24:69-78. [PMID: 25216628 DOI: 10.1517/13543784.2014.952368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
174 Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract. 2014;106:173-181. [PMID: 25193333 DOI: 10.1016/j.diabres.2014.08.009] [Cited by in Crossref: 154] [Cited by in F6Publishing: 161] [Article Influence: 19.3] [Reference Citation Analysis]
175 Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13:673-91. [PMID: 25131830 DOI: 10.1038/nrd4360] [Cited by in Crossref: 918] [Cited by in F6Publishing: 931] [Article Influence: 114.8] [Reference Citation Analysis]
176 Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol 2014;9:1736-46. [PMID: 24877719 DOI: 10.1021/cb500235n] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
177 Sardiu ME, Smith KT, Groppe BD, Gilmore JM, Saraf A, Egidy R, Peak A, Seidel CW, Florens L, Workman JL, Washburn MP. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network. Mol Cell Proteomics 2014;13:3114-25. [PMID: 25073741 DOI: 10.1074/mcp.M113.037127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
178 Alsarraf O, Fan J, Dahrouj M, Chou CJ, Menick DR, Crosson CE. Acetylation: a lysine modification with neuroprotective effects in ischemic retinal degeneration. Exp Eye Res 2014;127:124-31. [PMID: 25064603 DOI: 10.1016/j.exer.2014.07.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
179 Blackmore JK, Karmakar S, Gu G, Chaubal V, Wang L, Li W, Smith CL. The SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis. Endocrinology 2014;155:3251-61. [PMID: 24971610 DOI: 10.1210/en.2014-1002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
180 McCauley BS, Dang W. Histone methylation and aging: lessons learned from model systems. Biochim Biophys Acta 2014;1839:1454-62. [PMID: 24859460 DOI: 10.1016/j.bbagrm.2014.05.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
181 Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014;4:e207. [PMID: 24786391 DOI: 10.1038/bcj.2014.29] [Cited by in Crossref: 65] [Cited by in F6Publishing: 85] [Article Influence: 8.1] [Reference Citation Analysis]
182 Simhadri C, Daze KD, Douglas SF, Quon TTH, Dev A, Gignac MC, Peng F, Heller M, Boulanger MJ, Wulff JE, Hof F. Chromodomain Antagonists That Target the Polycomb-Group Methyllysine Reader Protein Chromobox Homolog 7 (CBX7). J Med Chem 2014;57:2874-83. [DOI: 10.1021/jm401487x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
183 Bergadà L, Yeramian A, Sorolla A, Matias-Guiu X, Dolcet X. Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation. PLoS One 2014;9:e92764. [PMID: 24651472 DOI: 10.1371/journal.pone.0092764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
184 Marquez-Curtis LA, Qiu Y, Xu A, Janowska-Wieczorek A. Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic Acid. Stem Cells Int 2014;2014:610495. [PMID: 24757448 DOI: 10.1155/2014/610495] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
185 Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 2014;5:265-96. [PMID: 24622842 DOI: 10.1007/s13238-014-0031-6] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 10.8] [Reference Citation Analysis]
186 Roca H, Pande M, Huo JS, Hernandez J, Cavalcoli JD, Pienta KJ, McEachin RC. A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial - mesenchymal cell reprogramming and cancer progression. BMC Syst Biol 2014;8:29. [PMID: 24612742 DOI: 10.1186/1752-0509-8-29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
187 Venkatraman A, Hu YS, Didonna A, Cvetanovic M, Krbanjevic A, Bilesimo P, Opal P. The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1. Hum Mol Genet 2014;23:3733-45. [PMID: 24594842 DOI: 10.1093/hmg/ddu081] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
188 Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). Expert Opin Ther Pat 2014;24:401-15. [PMID: 24397271 DOI: 10.1517/13543776.2014.877446] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
189 Treppendahl MB, Kristensen LS, Grønbæk K. Predicting response to epigenetic therapy. J Clin Invest 2014;124:47-55. [PMID: 24382389 DOI: 10.1172/JCI69737] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
190 Nagai Y, Limberis MP, Zhang H. Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway. Gene Ther 2014;21:219-24. [PMID: 24385144 DOI: 10.1038/gt.2013.78] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
191 West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30-9. [PMID: 24382387 DOI: 10.1172/JCI69738] [Cited by in Crossref: 832] [Cited by in F6Publishing: 855] [Article Influence: 104.0] [Reference Citation Analysis]
192 Hoffmann G, Breitenbücher F, Schuler M, Ehrenhofer-Murray AE. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem 2014;289:5208-16. [PMID: 24379401 DOI: 10.1074/jbc.M113.487736] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
193 Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, Nguyên TL, Di Lenardo T, Semmes OJ, Lin R, Hiscott J. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J Virol 2014;88:2927-40. [PMID: 24371063 DOI: 10.1128/JVI.03406-13] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
194 Mounce BC, Mboko WP, Kanack AJ, Tarakanova VL. Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection. J Virol 2014;88:2268-78. [PMID: 24335310 DOI: 10.1128/JVI.03278-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
195 Cho M, Choi E, Kim JH, Kim H, Kim HM, Lee JI, Hwang K, Kim H, Han G. Lactam-Based HDAC Inhibitors for Anticancer Chemotherapy: Restoration of RUNX3 by Posttranslational Modification and Epigenetic Control. ChemMedChem 2014;9:649-56. [DOI: 10.1002/cmdc.201300393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
196 Ning C, Bi Y, He Y, Huang W, Liu L, Li Y, Zhang S, Liu X, Yu N. Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 2013;23:6432-5. [DOI: 10.1016/j.bmcl.2013.09.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
197 Lan MY, Yang WL, Lin KT, Lin JC, Shann YJ, Ho CY, Huang CY. Using computational strategies to predict potential drugs for nasopharyngeal carcinoma. Head Neck 2014;36:1398-407. [PMID: 24038431 DOI: 10.1002/hed.23464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
198 Girardini JE, Marotta C, Del Sal G. Disarming mutant p53 oncogenic function. Pharmacol Res 2014;79:75-87. [PMID: 24246451 DOI: 10.1016/j.phrs.2013.11.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
199 Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014;25:42-52. [PMID: 24140022 DOI: 10.1016/j.tem.2013.09.002] [Cited by in Crossref: 424] [Cited by in F6Publishing: 470] [Article Influence: 47.1] [Reference Citation Analysis]
200 Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One 2013;8:e77684. [PMID: 24155971 DOI: 10.1371/journal.pone.0077684] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
201 Yamamura A, Miura K, Karasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushige S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. Biochem Biophys Res Commun 2013;441:102-7. [PMID: 24134849 DOI: 10.1016/j.bbrc.2013.10.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
202 Lötsch J, Schneider G, Reker D, Parnham MJ, Schneider P, Geisslinger G, Doehring A. Common non-epigenetic drugs as epigenetic modulators. Trends Mol Med 2013;19:742-53. [PMID: 24054876 DOI: 10.1016/j.molmed.2013.08.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
203 Torgersen ML, Engedal N, Bøe SO, Hokland P, Simonsen A. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood 2013;122:2467-76. [PMID: 23970379 DOI: 10.1182/blood-2013-05-500629] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 7.7] [Reference Citation Analysis]
204 Blattmann C, Thiemann M, Stenzinger A, Christmann A, Roth E, Ehemann V, Debus J, Kulozik AE, Weichert W, Huber PE, Oertel S, Abdollahi A. Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. Strahlenther Onkol 2013;189:957-66. [PMID: 23801068 DOI: 10.1007/s00066-013-0372-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
205 Adwan L, Zawia NH. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther 2013;139:41-50. [PMID: 23562602 DOI: 10.1016/j.pharmthera.2013.03.010] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
206 Omolo B, Carson C, Chu H, Zhou Y, Simpson DA, Hesse JE, Paules RS, Nyhan KC, Ibrahim JG, Kaufmann WK. A prognostic signature of G(2) checkpoint function in melanoma cell lines. Cell Cycle 2013;12:1071-82. [PMID: 23454897 DOI: 10.4161/cc.24067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
207 Esteller M. Cancer, epigenetics and the Nobel Prizes. Mol Oncol 2012;6:565-6. [PMID: 23141798 DOI: 10.1016/j.molonc.2012.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
208 New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6:637-56. [PMID: 23141799 DOI: 10.1016/j.molonc.2012.09.003] [Cited by in Crossref: 217] [Cited by in F6Publishing: 204] [Article Influence: 21.7] [Reference Citation Analysis]